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Abstract Studies suggest that patients with relapsing-
remitting multiple sclerosis (RRMS) who do not benefit
from other disease-modifying treatments (DMTs) may
benefit from converting to glatiramer acetate (GA). COP-
TIMIZE was a 24-month observational study designed to
assess the disease course of patients converting to GA
20 mg daily from another DMT. Eligible patients had
converted to GA and had received prior DMT for
3–6 months, depending on the reasons for conversion.
Patients were assessed at baseline and at 6, 12, 18, and
24 months. In total, 672 patients from 148 centers world-
wide were included in the analysis. Change of therapy to
GA was prompted primarily by lack of efficacy (53.6 %) or
intolerable adverse events (AEs; 44.8 %). Over a 24-month
period, 72.7 % of patients were relapse free. Mean annual
relapse rate decreased from 0.86 [95 % confidence interval
(CI) 0.81–0.91] before the change to 0.32 (95 % CI
0.26–0.40; p \ 0.0001) at last observation, while the pro-
gression of disability was halted, as the Kurtzke Expanded
Disability Status Scale (EDSS) scores remained stable.
Patients improved significantly (p \ 0.05) on measures of
fatigue, quality of life, depression, and cognition; mobility
scores remained stable. The results indicate that changing
RRMS patients to GA is associated with positive treatment
outcomes.
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Introduction
Multiple sclerosis (MS) is a chronic, progressive, autoim-
mune diffuse inflammatory disease of the central nervous
system [1]. Historically, the disease and the efficacy of MS
treatments were measured by the extent to which clinical
progression was slowed or halted, using relapse rates or the
progression of disability [2, 3]. However, we now know
that other considerations must also be taken into account,
including fatigue, quality of life (QoL), etc. [4]. At least
30 % of patients show a suboptimal response to first-line
disease-modifying treatments (DMTs) for relapsing-remit-
ting multiple sclerosis (RRMS) during the first year of
treatment [5]. There are no acceptable criteria to guide
physicians when converting from one first-line DMT to
another, and such decisions are generally based on the
physician’s judgment.
Studies have shown that the three most common reasons
why physicians in clinical practice convert an MS patient’s
medication are lack of efficacy or suboptimal response, [5,
6] intolerable drug-induced adverse events (AEs) [7, 8],
and the development of neutralizing antibodies [9–11],
which are known to block the biological activity of inter-
feron (IFN) and natalizumab therapy [12]. It has been
suggested that clinical observations such as relapse rate and
disability or findings of magnetic resonance imaging (MRI)
may be used to define criteria for converting from one
DMT to another in clinical practice [12, 13]. One study
analyzed whether the first relapse and time from the first to
second relapse would be able to predict treatment failure
[14]. However, none of these criteria has proved useful in
determining whether a patient would benefit from a treat-
ment change.
Converting therapy within the IFN-b class may not
always benefit the patient [15]. Patients who present with
neutralizing antibodies during IFN treatment do not ben-
efit from converting from one IFN to another or from
continuous therapy with any subcutaneous IFN-b prepa-
ration [15]. Conversely, studies have demonstrated that
there is a clinical benefit in changing either from one
class of first-line DMT to another or to second-line
treatments [13, 16–18]. With some DMTs (e.g. natal-
izumab, which is indicated for patients for whom IFN
therapy has not been effective), the use of escalating
doses has been proven to improve efficacy compared with
converting to another DMT [19]. However, despite its
efficacy profile, the safety and tolerability of natalizumab
are a concern because of the risk of progressive multi-
focal leukoencephalopathy (PML) [20].
The copolymer glatiramer acetate (GA; Copaxone) is
approved as a 20-mg daily subcutaneous (s.c.) injection for
reducing relapse frequency in patients with RRMS [21].
Post-marketing experience with GA includes more than
1.88 million patient-years of exposure and, in some
patients, more than 20 consecutive years of treatment [22].
Two prospective open-label studies have shown a benefi-
cial effect of GA for subjects who did not benefit from
previous sequential IFN treatment, either because of lack of
perceived clinical effects or AEs [13, 17]. The COPTIM-
IZE trial was designed to provide insight into patients’
outcomes and attitudes toward converting to GA when
another DMT is ineffective or intolerable. This also
allowed investigators to assess the impact of the mild
adverse effect profile of GA, which differs in many ways




COPTIMIZE was a 2-year international, multicenter, pro-
spective, non-interventional, longitudinal, and observational
study conducted in 148 study centers across 19 countries.
Included were patients who had converted from another
DMT to GA 20 mg daily within 3–6 months of screening.
An electronic case report form (eCRF) was completed
by attending neurologists (investigators) to assess the dis-
ease course and rationale for converting treatment to GA.
Data were collected by means of standardized eCRF on a
password-protected website, at baseline and then at
6-month intervals for a total of five data collection time
points over 24 months. Baseline assessment included
patients’ demographic characteristics, MS disease history,
reasons for changing medication, annualized relapse rate
(ARR) in the 2 years before the conversion, expanded
disability status scale (EDSS)/mobility score measured
within 2 years before the conversion and at recruitment,
MRI data, cognitive functions by Paced Auditory Serial
Addition Test (PASAT) [26], and impact of fatigue on
daily activities by Modified Fatigue Impact Scale (MFIS;
the effects of fatigue on physical, cognitive, and psycho-
social functioning) [27]. Patients answered 21 questions on
fatigue severity, with scores ranging from ‘never’ (0) to
‘highly’ (4), which denotes severe fatigue.
Assessments at 6-month intervals included relapses
within the previous 6 months and the EDSS/mobility score;
the EDSS assessment was performed via the Neurostatus
e test [28]. Confirmed progression (i.e. worsening of the
EDSS from baseline to final examination) was defined as
an increase of one point if the baseline EDSS score was
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between 0 and 5, and by an increase of 0.5 points if the
baseline score was [5.0. Changes in function were asses-
sed by the Functional Assessment of Multiple Sclerosis
(FAMS) [29]. Scores on the FAMS range between 0.00 and
176.00 points, with an increase in score indicating an
increase in functional abilities. Depression was measured
by the Center for Epidemiological Studies Depression
Scale (CES-D) [30]. CES-D scores ranged from 0 to 60
points, with higher scores indicating more symptoms of
depression during the past week.
Patients
To be included, patients had to have a diagnosis of RRMS,
to have converted to GA within 3 months before recruit-
ment, and to have available ARR and EDSS data acquired
in the year before inclusion. Patients could have been
treated with any DMT for up to 6 months before the
treatment conversion, if the change was due to unverified
drug inefficacy or AEs.
Patients were classified based on their individual pre-
medication: ‘de novo’ patients had not received any phar-
maceutical MS medication, ‘converter’ patients had
received another kind of DMT before recruitment, and
‘post-chemotherapy’ patients had received chemothera-
peutic medication before recruitment.
Study endpoints
The primary study endpoint was disease course of subjects
converted from one DMT class (IFN) to another (GA) as
measured by ARR before and after the conversion, annu-
alized rate of deterioration (ARD: rate of deterioration as
measured by mean EDSS), and mobility score in the year
before and following the change to GA.
Secondary endpoints included reasons for changing
DMT; characteristics of patients failing to benefit from
previous DMT; QoL changes measured by FAMS follow-
ing GA conversion; impact of fatigue on daily activities,
measured by the MFIS; change in rates of depression as
evaluated by CES-D; and changes in AEs before and after
the conversion to GA.
This study was conducted in accordance with the 18th
World Medical Assembly (Helsinki) recommendations and
amendments, as well as guidelines for Good Epidemiology
Practice. Patients’ personal data and investigator data
included in the sponsor database were treated in compli-
ance with all local applicable laws and regulations.
Statistical analyses
The intention-to-treat cohort, consisting of all enrolled
subjects who took at least one dose of GA, was used for all
efficacy and safety assessments. Descriptive procedures
were used to represent data. Tests of significance (signed
rank test and binomial test) were used to measure changes
in efficacy parameters from baseline to final examination.
Wilcoxon signal rank was used within groups for EDSS,
MFIS, QoL, CES-D, and PASAT (excluding ARR).
Kruskal–Wallis was used between groups for EDSS.
Poisson regression within and between groups was used for
ARR. ARR and ARD before and after the conversion was
analyzed using repeated measures analysis of covariance
using the maximum likelihood ratio. Log transformation
was implemented to the ARR and ARD to establish if there
was a significant deviation of ARR and ARD from nor-
mality (i.e. if p \ 0.001 on the Shapiro–Wilk test).
Results
Patient disposition
A total of 672 patients were enrolled in the study. Data on
555 patients (82.6 %) were available at 365 days, and data
on 423 (63.0 %) were available at 730 days. The mean
duration of observation was 594.7 days [±standard devia-
tion (SD) = 221.3] in 634 patients who had one or more
examinations. Table 1 details patient demographics and
disease characteristics.
Baseline demographics and patient classification
Demographics and disease characteristics are shown in
Table 1. Of the 672 patients enrolled, 640 (95.2 %) were
classified as ‘converter’ patients (had received other DMT
before enrollment), and the efficacy analysis was restricted
to these patients. Nine (1.3 %) were classified as ‘post-
chemotherapy’ patients, and 23 patients (3.4 %) were
missing classification data. In converted patients, a change
of therapy to GA was prompted primarily by lack of effi-
cacy (343/640; 53.6 %) or intolerable AEs (287/640;
44.8 %), caused by the corresponding premedication.
[Note: The number of patients who changed to GA due to a
lack of efficacy (343) and the number that changed due to
AEs (287) sums to 630, not 640, as there are multiple
reasons aside from these two that were cited by patients for
changing therapy]. In the majority of converted patients
(553/640; 86.4 %), only a single DMT agent had been used
before the conversion to GA therapy. Eighty patients
(12.5 %) had received two DMT agents, and six patients
(0.9 %) had received three DMT agents before the change
to GA. One patient (0.2 %) was missing information on
number of prior DMT treatments received.
Of the patients converted, documentation on type of
DMT was available for 617 patients and missing for 23
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patients. Most patients converted (589/617) (95.5 %) had
received IFN-b before converting (Fig. 1).
Table 2 details the baseline disease characteristics of
those patients who were converted because of lack of
efficacy or because of AEs. The clinical type of disease,
disease activity over the past 2 years, and the decision to
convert were significantly different between these two
groups. A greater proportion of patients who converted
because of lack of efficacy presented with RRMS with
incomplete remissions, while most who converted because
of AEs had RRMS with complete remissions. Exacerba-
tions tended to be rare in both groups. However, exacer-
bations of disease were more frequent in those who were
converted because of lack of efficacy, while stable disease
was more prominent in those who were converted because
of AEs. While, in most cases, the decision to convert was
made solely by the patient’s physician, a mutual decision
was more common among the patients who converted
because of AEs (Table 2). The majority of patients who
converted because of AEs discontinued IFN therapy
because of flu-like symptoms [180/287 (62.7 %); Table 3].
Among the nine patients classified as being ‘post-che-
motherapy’, the most common reasons for converting were
worsening of EDSS (n = 7) and severity of relapses
(n = 4), followed by high lesion load on MRI (n = 2) and
a high relapse rate (n = 1). Multiple reasons for converting
could be recorded for a single patient. All nine patients had
undergone escalation therapy, seven had received
mitoxantrone, one had received cyclophosphamide, and
one cyclophosphamide followed by IFN.
Efficacy of GA
ARR
Data on ARRs before converting to GA and during the study
were available for 625 patients. The majority of these
patients [n = 458/625 (73.3 %)] experienced less than 0.25
relapses/year while receiving GA therapy (Fig. 2). Overall,
patients experienced a significant reduction in the mean
number of relapses from baseline while on GA therapy from
0.86 to 0.32 (mean change -0.54; p \ 0.0001 Chi squared;
Fig. 3). Reductions in ARR from baseline were significant
regardless of whether patients converted because of lack of
efficacy or AEs (mean change -0.66 and -0.36, respec-
tively; p \ 0.0001 in both groups; Fig. 3). However, the
decrease in ARR was significantly greater in patients con-
verting for lack of efficacy versus AEs (p = 0.0021).
Confirmed EDSS change
Data on 399 patients with at least one confirmed EDSS pro-
gression after baseline examination were evaluated. The
proportion of patients without confirmed progression (343/
399 patients, 86.0 %) was significantly higher than with
confirmed progression (56/399 patients; 14.0 %; p \ 0.0001,
binominal-test with H0 proportion = 50 %). When analyzed
by reason for conversion only, patients who converted
because of intolerable AEs had a significant increase in EDSS
from baseline (?0.17; p = 0.0265, Fig. 4a) but there was no
significant difference between the values in the two groups.
Mobility score
A total of 542 patients had at least one mobility score after
the baseline examination. The majority of patients
(n = 348; 64.2 %) did not experience any worsening in
Table 1 Baseline demographics and disease characteristics
Characteristics Patients with data Overall
Female gender, n (%) 672 476 (70.8)
Mean age, years (SD) 672 39.9 (10.2)
Mean duration of disease since
onset, mo (SD)
615 97.2 (78.9)
Mean time since MS diagnosis, mo
(SD)
632 69.7 (61.3)
Median ARR measured over the
past 2 years before GA (SD)
625 0.86 (0.67)




C1 and \3 318 (48.2)
C3 13 (2.0)




RRMS with complete remission 383 (58.3)
Clinically isolated syndrome 1 (0.2)
Other 9 (1.4)
Mean EDSS score measured over
the past 2 years before GA (SD)
878 2.8 (1.7)
Mean EDSS score at time of
conversion (SD)
600 3.0 (1.9)
Mobility score, n (%) 595
Asymptomatic 111 (18.7)
Able to walk unaided [500 m 336 (56.5)
Able to walk unaided
for \500 m
60 (10.1)
Walking with unilateral support 51 (8.6)
Walking with bilateral support 22 (3.7)
Need of wheelchair outdoors 15 (2.5)
MRI data available, n (%) 672 193 (41.0)
ARR annualized relapse rate, EDSS Expanded Disability Status Scale,
GA glatiramer acetate, MRI magnetic resonance imaging, MS multiple
sclerosis, RRMS relapsing-remitting multiple sclerosis, SD standard
deviation
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mobility A total of 103 (19.0 %) patients reported better
mobility, while 91 (16.8 %) reported worse mobility. The
difference in the numbers of patients showing improve-
ment or worsening was not significant by binominal test
with H0 proportion = 50 % (p = NS).
Impact on fatigue
Data on 287 patients with MFIS scores were available for
evaluation. Overall, mean MFIS scores decreased
significantly from baseline to final examination, with a
difference of -3.59 points ±15.05, p \ 0.0001; Table 4.
The reduction in fatigue was greater in patients who con-
verted because of lack of efficacy (-6.01 points from
baseline; p = 0.0006), compared with those who converted
because of AEs (-2.16 points; p = NS; Fig. 4b).
Change in QoL
A total of 218 patients had available QoL data at baseline
and at the final examination.
A significant improvement in QoL score of 5.94
(±31.57; p = 0.0227) from baseline to final examination
was reported (Table 4). QoL improved regardless of the
reasons for treatment conversion. Greater improvement
was observed in patients who converted because of AEs
(?10.81 points from baseline; p = 0.0120), compared with
those who converted because of lack of efficacy (?6.62
points; p = NS; Fig. 4c).
Depression
Data on 299 patients were available for evaluation. There
was a significant improvement overall in the depression
score following the conversion to GA therapy (-
1.50 ± 10.84 from baseline; Table 4). Improvement was
most commonly observed in patients who were converted
because of lack of efficacy (-4.48 points from baseline;
p \ 0.0001). No improvement was reported in those who
converted because of AEs (?0.58 points; p = NS; Fig. 4d).
Cognition changes
In the 72 patients for whom cognition (PASAT) data were
available, scores improved by a mean of 4.29 ± 9.28
(p \ 0.0001; Table 4). Improvement in cognition was
observed in patients who converted because of AEs (?3.26
points from baseline; p = 0.0088), as well as in those who











































 %Fig. 1 Type of disease-
modifying therapy used by
patients before converting to
glatiramer acetate in patients
with previous type known
(n = 617). IFN interferon, i.m
intramuscular, i.v. intravenous,
s.c subcutaneous
Table 2 Disease characteristics of patients converted to glatiramer
















Activity of disease over the past 2 years, % \0.0001




Slow progression (\ 1






Fast progression (C1 point
increase in EDSS in the
last year)
3.2 1.0
Could not be classified 4.4 2.5




EDSS Expanded Disability Status Scale, MS multiple sclerosis, RRMS
relapsing remitting MS
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baseline; p = NS; Fig. 4e). Both baseline and final scores
were notably higher in the group that converted because of
AEs (Fig. 4e).
Patient reporting of efficacy
Among the 660 patients with available data, only 49
patients (7.4 %; p \ 0.0001) reported that GA was
less effective than their previous DMT, while signif-
icantly more patients [348 (52.7 %)] reported that GA
treatment was more effective than their previous
DMT, and 263 patients (39.9 %) reported no
difference.
Safety and tolerability
A total of 196 AEs occurred in 104 patients [15.5 % of
all patients (n = 672)], with the majority of events
deemed probably [104 events in 56 patients (8.3 %)] or
possibly related to GA therapy [45 events in 26 patients
(3.8 %)]. Most common AEs by preferred term and sys-
tem organ class are shown in Table 5 in addition to AEs
by severity reported. 174 of all 672 patients (25.9 %)
terminated GA treatment during the observation period.









































ARR Quartile  
Pre-conversion Post-conversion
Fig. 2 Distribution of
annualized relapse rates (ARRs)
before and during glatiramer
acetate therapy (n = 625).
Patients with a very high
annualized relapse rate
terminated glatiramer acetate
treatment after a short period of


























Overall (n=625)* Lack of efficacy (n=343) Adverse events (n=287)
Fig. 3 Change in annualized relapse rate (ARR) in all patients
receiving glatiramer acetate (GA) therapy (n = 625) and in patients
with known reason for the conversion to GA (Asterisk denotes that the
overall number of patients with ARR data does not equal the sum of
the number of patients who converted to GA due to lack of efficacy
and adverse events because of double counting of patients who
reported both reasons for converting). All reductions in ARR within
groups were statistically significant (p \ 0.0001)
Table 3 Reasons for
discontinuing interferon
treatment before study entry
among patients converted to
glatiramer acetate because of
intolerable adverse events
(n = 287)








Skin reactions 51 (17.8)
Blood work 29 (10.1)
Others 64 (22.3)
Not specified 2 (0.7)
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Discussion
It is reported that patients with RRMS frequently convert
DMT because their original therapy is not optimally
effective or produces intolerable AEs [6, 7, 9, 12, 17–19];
those were the main reasons for converting to GA therapy
in this study. Depending on the reasons for converting, lack
of efficacy or adverse reactions, patients may have a
greater or lesser response to the new agent.
ARR is an important indication of the inflammatory
component of MS. In the COPTIMIZE study, ARR
was significantly reduced from baseline after convert-
ing to GA, both in patients who converted because of
lack of efficacy and those who converted because of
AEs.
No significant changes in EDSS scores were observed in
patients who were converted to GA therapy. However, it is
important to note that following the conversion to GA, a
greater proportion of patients had no confirmed progres-
sion, as measured by the EDSS; only modest changes in
EDSS scores from baseline were observed. Subgroup























































































































Lack of efficacy Adverse events
P=0.0088
Fig. 4 a Change in Expanded Disability Status Scale (EDSS) score
in patients converted to glatiramer acetate, by the reason for the
conversion. b Change in fatigue score (Modified Fatigue Impact
Scale) in patients converted to glatiramer acetate, by the reason for
the conversion. c Change in quality of life score (Functional
Assessment of Multiple Sclerosis) in patients converted to glatiramer
acetate, by the reason for the conversion. d Change in depression
score (Center for Epidemiological Studies Depression Scale) in
patients converted to glatiramer acetate, by the reason for the
conversion. e Change in cognition score (paced auditory serial
addition test) in converting patients by the reason for the conversion
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and final examination among those converted because of
lack of efficacy rather than AEs.
As our understanding of MS improves, it has become
clearer that symptoms beyond disability scores, such as
EDSS, are important [23]. For example, fatigue in MS has
been correlated not only with neurodegenerative processes
that cause functional reorganization resulting in increased
metabolic demands [31, 32], but also, recently, with dis-
turbance in central neuronal pathways [33]. Interestingly,
in one study, patient-reported fatigue was observed to
significantly improve after converting to GA, consistent
with previous reports of increased improvement of fatigue
symptoms with GA use [26, 34]. Similarly, cognition,
correlating with cortical atrophy in MS patients [35],
improved significantly from baseline after converting to
GA. Cognitive symptoms in MS have been associated with
cortical atrophy [35], but it is important to remember that
such symptoms in many patients can vary over time and be
a result of fatigue. Of course, patients who improve after
switching from IFN to GA may do so because they no
longer experience the typical flu-like side effects that
increase fatigue. Patients also improved significantly on
measures of QoL and depression, while mobility scores
remained stable. Improvements in QoL were more pro-
nounced in those who converted because of AEs versus
lack of efficacy, which is consistent with intolerable AEs,
which significantly impact QoL, being eliminated or
reduced after conversion to GA.
Depression scores significantly improved during GA
treatment in patients who converted due to lack of efficacy,
but were unchanged in those who converted because of
AEs. Improved scores in patients previously experiencing a
lack of efficacy may have been due to a heightened con-
fidence in the ability of their new regimen to slow disease
progression.
Taken together, the decrease in ARR and lack of EDSS
progression observed in patients who converted to GA
therapy represent significant real-world improvements
attained by RRMS patients whose disease was not ade-
quately controlled by their previous DMT. This is an
important finding, because it points to the ability of GA to
modify patient progression on a real-world level, as mea-
sured by clinical relapses and other patient-reported out-
comes, including fatigue and depression.
Of the 672 patients included in the study, AEs occurred
in 15.5 % of patients. These AEs were mainly attributable
to injection-site reactions or pain. Because neurodegener-
ative activity is observed in MS patients even in early
stages of the disease [36], it is important to establish rig-
orous algorithms to optimize treatment in those responding
sub-optimally to their original therapy. Should mono-
therapy not prove optimal, combining a DMT with another
treatment could provide an additive effect to control dis-
ease progression [37].
This observational study reflects both the limitations and
advantages inherent in such a study design. Regression to
the mean has been shown to be a common occurrence in
longitudinal studies of MS patients with high levels of
disease activity and may present a limitation in the present
study given that there is no comparison to a matched
control cohort [38]. This phenomenon would suggest that
patients switching to GA as a consequence of the limited
efficacy of prior therapy will tend to return to the average
disease state over time, potentially accounting for reduc-
tions in the ARR rate. Other limitations include the
potential for information or classification bias [39]. How-
ever, well-designed observational studies with appropriate
statistical techniques provide valuable information, with
high generalizability. Further, the overall sample size was
relatively small, and sample sizes were not consistent
throughout the different assessments (i.e. the same number
of patients may not have been examined for fatigue as for
cognition, etc.). Thus, it was not possible to pool the
patients across all parameters. Further, because of the
observational nature of this study, there was a fairly high
dropout rate and considerable variability in the availability
of patient data for different endpoints. However, the
dropout rate included not only patients who left the study
but also patients who had to be excluded from the study
because of missing data from the participating sites. Nev-
ertheless, the results of observational studies can be used to
demonstrate real-world clinical outcomes, including
Table 4 Change in secondary efficacy endpoints from baseline to final observation of all patients irrespective of previous treatment or reason for
conversion
Scale, mean (95 % CI) Patients with data (n) Baseline Final p value
Fatigue, MFIS 287 31.94 (29.67–34.22) 28.36 (26.00–30.72) \0.0001
Quality of life, FAMS 218 102.67 (97.78–107.57) 108.61 (103.43–113.80) 0.0227
Depression, CES-D 299 16.13 (14.85–17.40) 14.63 (13.38–15.88) 0.0111
Cognition, PASAT 72 37.46 (33.93–40.99) 41.75 (37.79–45.71) \0.0001
CES-D Center for Epidemiological Studies Depression Scale, CI confidence interval, FAMS Functional Assessment of Multiple Sclerosis, MFIS
Modified Fatigue Impact Scale, PASAT paced auditory serial addition test
2108 J Neurol (2014) 261:2101–2111
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improvement to patients’ daily lives, and fewer relapses
and improved quality of life.
Despite study limitations, our observations corroborate
the results of previous studies in which improved treatment
response (i.e. reduced ARR, delayed disease progression)
was observed in patients who converted from one DMT to
another [5, 6, 14, 40–43]. Our findings also emphasize the
importance of changing a therapeutic regimen to improve
patients’ well-being (i.e. QoL, depression, fatigue) and
control disease progression while overcoming treatment-
related barriers (i.e. intolerable AEs) that could compro-
mise compliance among patients responding sub-optimally
to their current regimen and result in further disease
progression.
Patients whose disease is progressing on their current
DMT need to be converted in a timely manner. Future
clinical trial designs should include patients converting
from one DMT to another as a study arm. These trials
could contribute to the development of consensus state-
ments, treatment algorithms, and clinical parameters for
Table 5 Most frequently reported adverse events by preferred term





Total reported adverse events 104 (15.5) 196
By system organ class (frequency of cases C3)
General disorders and administration
site conditions
50 (7.4) 78
Nervous system disorders 19 (2.8) 20
Skin and subcutaneous tissue disorders 18 (2.7) 21
Psychiatric disorders 11 (1.6) 14
Respiratory, thoracic and mediastinal
disorders
10 (1.5) 12
Musculoskeletal and connective tissue
disorders
8 (1.2) 9
Immune system disorders 7 (1.0) 7
Vascular disorders 7 (1.0) 7
Gastrointestinal disorders 5 (0.7) 6
Infections and infestations 3 (0.5) 3
Neoplasms benign, malignant, and
unspecified
3 (0.5) 3
Adverse events by preferred term (frequency of cases C4)
Injection-site pain 13 (1.9) 17
Injection-site reaction 10 (1.5) 10
Dyspnea 8 (1.2) 10
Depression 6 (0.9) 6
Hypersensitivity 6 (0.9) 6
Headache 5 (0.7) 5
Injection site induration 5 (0.7) 5
Lipoatrophy 5 (0.7) 5
Application site pain 4 (0.6) 4
Arthralgia 4 (0.6) 4
Fatigue 4 (0.6) 4
Flushing 4 (0.6) 4
Rash 4 (0.6) 4
Syncope 4 (0.6) 4
By severity
Serious 7 (1.0) 10
Severe 18 (2.7) 32
Moderate 56 (8.3) 90
Mild 41 (6.1) 61
Not reported 9 (1.3) 13
Most common severe adverse events
Injection-site pain 3 (0.5) 4
Dyspnea 4 (0.6) 4
Most common moderate adverse events
Injection-site pain 6 (0.9) 8






Injection-site reaction 6 (0.9) 4
Hypersensitivity 6 (0.9) 4
Most common mild adverse events
Injection-site pain 5 (0.7) 5
Injection-site reaction 5 (0.7) 5
Outcome of adverse events
Ongoing at date of report 49 (7.3) 79
Completely resolved 48 (7.1) 84
Resolved with sequelae 8 (1.2) 12
Data missing 9 (1.3) 11
Unknown result 4 (0.6) 10
Action taken on Copaxone due to adverse events
No action taken 71 (10.6) 128
Treatment permanently discontinued 31 (4.6) 46
Treatment temporarily interrupted 13 (1.9) 19
Data missing 2 (0.4) 2
Dose reduction 1 (0.2) 1




Reported no change after conversion to
GA
192 (29.0) N/A
Reported feeling worse after
conversion to GA
38 (5.8) N/A
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changing treatment. This is important, as converting
treatments is not always necessary and is associated with
significant healthcare costs.
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